机构地区:[1]华中科技大学同济医学院附属同济医院小儿外科,武汉430030
出 处:《中华实验外科杂志》2018年第2期245-249,共5页Chinese Journal of Experimental Surgery
基 金:国家自然科学基金(81200266)
摘 要:目的在小鼠肠缺血再灌注损伤(IR)模型探讨抗体阻断整合素α4β7(LPAM-1)减轻肠IR导致的损伤和炎性反应的作用。方法肠系膜上动脉夹闭造成小鼠肠IR损伤,经鼠尾动脉注射抗LPAM-1抗体。检测生存率、肠淋巴细胞的浸润、肠屏障损伤、肠组织乳酸水平、肺组织髓过氧物酶(MPO)活性、肺血管的通透性及血循环中细胞因子的水平。结果抗体阻断LPAM-1减轻了肠IR引起的淋巴细胞浸润[IR 8 h,Peyer淋巴结:(4.5±0.6)×10^6比(9.3±1.1)×10^6;固有层:(2.4±0.5)×10^6比(5.1±0.9)×10^6;黏膜层:(1.8±0.3)×10^6比(2.9±0.6)×10^6;IR 24 h,Peyer淋巴结:(3.9±0.8)×10^6比(5.7±0.5)×10^6;固有层:(2.1±0.2)×10^6比(2.9±0.4)×10^6;黏膜层:(0.9±0.2)×10^6比(1.4±0.4)×10^6],提高了IR后小鼠的生存率(IR 168 h,70%比45%),降低了肠通透性[IR 8 h,荧光素异硫氰酸酯-葡聚糖(FD4)清除率:(29.5±6.9) nl/(min·cm^2)比(48.3±8.1) nl/(min·cm^2);IR 24 h,(20.9±4.2) nl/(min·cm^2)比(33.8±4.5) nl/(min·cm^2)]、降低了肠乳酸水平[IR 8 h,乳酸含量:(11.6±2.3) μg/mg组织比(18.1±4.4) μg/mg组织;IR 24 h,(10.1±2.3) μg/mg组织比(14.2±2.7) μg/mg组织]、降低了肺MPO活性[IR 8 h,MPO活性:(7.6±1.7) U/g组织比(13.3±2.9) U/g组织;IR24 h,(4.8±0.9) U/g组织比(8.6±1.5) U/g组织]、降低了肺血管通透性[IR 8 h,吸光度(A)值:(4.7±0.6)×10^-2比(6.5±0.5)×10^-2;IR 24 h,A值:(3.4±0.5)×10^-2比(5.3±0.4×)10^-2]、降低循环中白细胞介素(IL)-1β、IL-6和肿瘤坏死因子(TNF)-α的水平[IR 8 h,IL-1β:(7.3±1.7) pg/mg比(14.3±2.8) pg/mg;TNF-α:(1.4±1.3) pg/mg比(2.0±0.3) pg/mg;IL-6:(4.6±5.5) pg/mg比(7.4±0.8) pg/mg;IR 24 h,IL-1β:(7.6±1.2) pg/mg比(10.1±1.6) pg/mg;TNF-�Objective To determine the effects of antibody blockade of α4β7 integrin (LPAM-1) on the intestinal injury and systemic inflammatory response after ischemia and reperfusion injury (IR).Methods Mice were subjected to IR, with or without treatment with LPAM-1 monoclonal antibody. The intestinal injury and systemic inflammatory responsewas determined by examining lymphocyte infiltration, intestinal permeability, intestinal lactate levels, lung myeloperoxidase activity (MPO), lung vascular permeability and serum cytokine levels. Survival of the mice was determined over a one week time period.Results Antibody blockade of LPAM-1 attenuated the increased lymphocyte infiltration after IR [IR 8 h, Peyer patch: (4.5±0.6)×10^6 vs. (9.3±1.1)×10^6; lamina propria: (2.4±0.5)×10^6 vs. (5.1±0.9)×10^6; mucosa: (1.8±0.3)×10^6 vs. (2.9±0.6)×10^6; IR 24 h, Peyer patch: (3.9±0.8)×10^6 vs. (5.7±0.5)×10^6; lamina propria: (2.1±0.2)×10^6 vs. (2.9±0.4)×10^6; mucosa: (0.9±0.2)×10^6 vs. (1.4±0.4)×10^6]. Antibody blockade of LPAM-1 improved survivial (IR 168 h, 70% vs. 45%), gut permeability [IR 8 h, fluoresceinisothiocyanate dextran (FD4) clearance: (29.5±6.9) vs. (48.3±8.1) nl/(min·cm^2); IR 24 h, (20.9±4.2) vs. (33.8±4.5) nl/(min·cm2)], intestinal lactate levels [IR 8 h, lactate level: (11.6±2.3) vs. (18.1±4.4) μg/mg; IR 24 h, (10.1±2.3) vs. (14.2±2.7) μg/mg], lung myeloperoxidase activity (IR 8 h, MPO activity: (7.6±1.7) vs. (13.3±2.9) U/g; IR 24 h, (4.8±0.9) vs. (8.6±1.5) U/g], lung vascular permeability [IR 8 h, A values: (4.7±0.6)×10^-2 vs. (6.5±0.5)×10^-2; IR 24 h, (3.4±0.5)×10^-2 vs. (5.3±0.4)×10^-2)] and serum levels of interleukine-1β (IL-1β), interleukine-6 (IL-6), tumor necrosis factor-α (TNF-α) [IR 8 h, IL-1β: (7.3±1.7) vs. (14.3±2.8) pg/mg; TNF-α: (1.4±1.3) vs. (2.0±0.3) pg/
关 键 词:小肠 缺血 再灌注 系统性炎性反应综合征
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...